Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reducing risk in thiopurine therapy.

Xenobiotica; the fate of foreign compounds in biological systems - 1 Jan 2020

Marinaki Anthony M, Arenas-Hernandez Monica

Abstract excerpt

The thiopurine drugs azathioprine and mercaptopurine are effective in the treatment of disorders of immune regulation and acute lymphoblastic leukaemia. Although developed in the 1950s, thiopurines remained relevant in the anti-tumour necrosis factor biologic era, finding widespread use as a co-immunomodulator. Step changes in the management of patients treated with thiopurines have reduced the incidence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Methyltransferases
Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azathioprine

Share to Drug Hypersensitivity

Share to Erythrocytes

Share to Mercaptopurine

Share to Purine-Pyrimidine Metabolism, Inborn Errors

Share to Purines

Source

Identifiers

PMID: 31682552
DOI: 10.1080/00498254.2019.1688424

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reducing risk in thiopurine therapy.PMID 31682552Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT 15 Genotypes: 2018 UpdateSemantic proximity Read ↗

Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?Semantic proximity Read ↗

Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: It takes two to tangoSemantic proximity Read ↗

Personalization of thiopurine therapy: Current recommendations and future perspectives.Semantic proximity Read ↗

Clinical pharmacogenomics of thiopurine S-methyltransferase.Semantic proximity Read ↗

An integrated triple approach - TPMT phenotype, NUDT-15 genotype, and therapeutic drug monitoring of thiopurine metabolites for optimal clinical efficacy: a case series.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.Semantic proximity Read ↗

Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.Semantic proximity Read ↗

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression riskSemantic proximity Read ↗

Importance of NUDT15 Polymorphisms in Thiopurine TreatmentsSemantic proximity Read ↗

Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.